Literature DB >> 19444260

Is it possible to reduce cardiovascular risk with glucose-lowering approaches?

Hertzel C Gerstein1.   

Abstract

Diabetes mellitus is a strong, independent risk factor for cardiovascular events, and a key determinant of the level of this risk is the degree of glucose elevation. Clinical trials have not demonstrated that lowering glucose levels in people with established, long-duration diabetes mellitus has a clear cardiovascular benefit, and one trial reported that this approach increased mortality. In individuals with recent-onset diabetes mellitus, however, control of glucose level has established benefits on diabetes-related eye disease and kidney disease (which are themselves cardiovascular risk factors), and 10 years of intensive glucose control in these patients reduces the 15-20-year risk of myocardial infarction and mortality. These observations, along with the facts that the prevalence of diabetes mellitus is growing and that people typically have the disease for 20-40 years of their lives, support the importance of controlling glucose level and preventing its progressive rise over time. Currently available evidence suggests that therapeutic efforts that target hyperglycemia early in the course of diabetes have a long-term cardiovascular benefit.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19444260     DOI: 10.1038/nrendo.2009.49

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  32 in total

1.  Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study.

Authors:  Elizabeth Selvin; Josef Coresh; Sherita H Golden; Frederick L Brancati; Aaron R Folsom; Michael W Steffes
Journal:  Arch Intern Med       Date:  2005-09-12

2.  Blood glucose and risk of cardiovascular disease in the Asia Pacific region.

Authors:  C M M Lawes; V Parag; D A Bennett; I Suh; T H Lam; G Whitlock; F Barzi; M Woodward
Journal:  Diabetes Care       Date:  2004-12       Impact factor: 19.112

3.  Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.

Authors:  M Shichiri; H Kishikawa; Y Ohkubo; N Wake
Journal:  Diabetes Care       Date:  2000-04       Impact factor: 19.112

Review 4.  Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.

Authors:  Elizabeth Selvin; Shari Bolen; Hsin-Chieh Yeh; Crystal Wiley; Lisa M Wilson; Spyridon S Marinopoulos; Leonard Feldman; Jason Vassy; Renee Wilson; Eric B Bass; Frederick L Brancati
Journal:  Arch Intern Med       Date:  2008-10-27

5.  Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.

Authors:  Elizabeth Selvin; Spyridon Marinopoulos; Gail Berkenblit; Tejal Rami; Frederick L Brancati; Neil R Powe; Sherita Hill Golden
Journal:  Ann Intern Med       Date:  2004-09-21       Impact factor: 25.391

6.  Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes.

Authors:  Donna H Ryan; Mark A Espeland; Gary D Foster; Steven M Haffner; Van S Hubbard; Karen C Johnson; Steven E Kahn; William C Knowler; Susan Z Yanovski
Journal:  Control Clin Trials       Date:  2003-10

7.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

8.  Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.

Authors:  Robert M Califf; Mitradev Boolell; Steven M Haffner; M Angelyn Bethel; John McMurray; Anil Duggal; Rury R Holman
Journal:  Am Heart J       Date:  2008-10       Impact factor: 4.749

9.  Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).

Authors:  Hertzel Gerstein; Salim Yusuf; Matthew C Riddle; Lars Ryden; Jackie Bosch
Journal:  Am Heart J       Date:  2007-11-26       Impact factor: 4.749

10.  Rosiglitazone RECORD study: glucose control outcomes at 18 months.

Authors:  P D Home; N P Jones; S J Pocock; H Beck-Nielsen; R Gomis; M Hanefeld; M Komajda; P Curtis
Journal:  Diabet Med       Date:  2007-06       Impact factor: 4.359

View more
  2 in total

1.  Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study.

Authors:  H C Gerstein; S Islam; S Anand; W Almahmeed; A Damasceno; A Dans; C C Lang; M A Luna; M McQueen; S Rangarajan; A Rosengren; X Wang; S Yusuf
Journal:  Diabetologia       Date:  2010-08-14       Impact factor: 10.122

2.  Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort study.

Authors:  Casper H Jørgensen; Gunnar H Gislason; Charlotte Andersson; Ole Ahlehoff; Mette Charlot; Tina K Schramm; Allan Vaag; Steen Z Abildstrøm; Christian Torp-Pedersen; Peter R Hansen
Journal:  Cardiovasc Diabetol       Date:  2010-09-16       Impact factor: 9.951

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.